Cancer Biology | Journal of Cancer Biology & Research | Open Access Journal | Study, Review | JSciMed Central
  • Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2373-9436
    Current Issue
    Volume 7, Issue 1
    Short Communication
    Andras G. Lacko*
    Neuroblastoma (NB) is the most common cancer diagnosed in infants and the most common extra-cranial solid tumor in children. The clinical course of the disease is highly variable with frequent spontaneous regressions observed in patients less than 1 year of age, while it presents with a much higher risk of a poor prognosis in older pediatric patients. Due to the heterogeneous presentation of NB, stratification of patients via numerous diagnostic procedures, and subsequent appropriate treatment strategies conforming to the varying stages of aggressiveness of the disease have been developed.
    Design and execution and evaluation of the findings of clinical studies involving NB patients have been performed largely by a select groups of experts leading to substantially deeper knowledge of the pathophysiological mechanism(s) and the diagnosis of NB while still leaving a lot more effort to be expanded for substantially improving the prognoses for patients, especially those with medium and high risk disease.
    Several exhaustive reviews are currently available on NB therapeutics including accounts of clinical trials. This brief overview intends to examine only some of the currently available treatment strategies, regarding their respective therapeutic efficacies, including a focus on long and short term toxic off target effects. A brief assessment of potential opportunities, with a special emphasis on nanotherapeutics, for achieving improved outcomes for NB patients is also included.
  • Current Issue Highlights
  • BRAT1 was originally identified as a BRCA1 interacting protein [1], however, subsequent studies showed that it also binds to ATM, DNA-PK, and SMC1,

    Mechanisms of detecting and repairing damaged DNA are conserved and controlled through the DNA damage response (DDR).

    JSciMed Central Peer-reviewed Open Access Journals
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at Permissions beyond the scope of this license may be available at